Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that are utilized in multiple therapeutic modalities, such as T cell ...

2022—Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) TCR and BCR kits, a family of multiplex-PCR, NGS-based assays that enable profiling of up to all seven T ...

TAC T-cell therapy is a new cancer treatment option. Researchers are studying it to treat both solid tumors and blood cancers, including multiple myeloma. If it gets FDA approval, this treatment would ...

The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ...

This article and associated images are based on a poster originally authored by Alex Chenchik, Lester Kobzik, Tianbing Liu, Dongfang Hu, Kitt Paraiso, Khadija Ghias, and Paul Diehl and presented at ...

Cancer immunotherapy approaches such as adoptive transfer of chimeric antigen receptor (CAR) T cells or tumor-infiltrating lymphocytes have yielded promising results in hematological malignancies.

SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars ...